The FDA approved new Foundation Medicine companion diagnostics tied to Pfizer’s prostate cancer regimen, extending the clinical footprint of FoundationOne CDx as a decision tool for specific molecular subgroups. Separately, Foundation Medicine also received FDA clearance for a breast cancer CDx tied to biomarker testing that includes genomic features used for treatment stratification. For commercialization and adoption, the approvals reinforce Foundation’s role in matching targeted oncology therapies with biomarker-defined patients, particularly in settings where testing consistency and turnaround time drive real-world uptake. While these are diagnostic actions rather than drug approvals, they often become gating items for payer coverage and treatment pathways—turning lab performance and reporting workflows into strategic differentiators. The net effect is a broader network of FDA-recognized biomarker evidence built around Foundation Medicine’s tissue-based next-generation sequencing format.